Expertise in
4
conditions

Dr. Pratima Chalasani

Hematology
Carle Foundation Hospital
611 W Park St, 
Urbana, IL 
Expertise in
4
conditions
Carle Foundation Hospital
611 W Park St, 
Urbana, IL 

Overview

Pratima Chalasani is a Hematologist practicing medicine in Urbana, Illinois.

Dr. Chalasani is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Anemia, and Gallbladder Adenocarcinoma.

She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 17 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IL

Hospital Affiliations

Carle Hoopeston Regional Health Center
Kirby Medical Center
Carle Bromenn Medical Center
Carle Foundation Hospital
Sarah Bush Lincoln Health Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Carle Foundation Hospital
611 W Park St, Urbana, IL 61801
Other Locations
Carle Rx Express
200 Lerna Rd S, Mattoon, IL 61938

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other
Study Phase: Early Phase 1
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Journal: Cancer chemotherapy and pharmacology
Published: October 01, 2012
Similar Doctors
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Referral may be required

Carle Foundation Hospital

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
309-624-9856
Languages Spoken:
English
See accepted insurances

Connie Piccone is a Hematologist and an Oncologist practicing medicine in Urbana, Illinois. Dr. Piccone is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Gallbladder Removal.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Carle Foundation Hospital

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
217-383-6636
Experience:
18+ years
Languages Spoken:
English, Hindi, Russian, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Priyankkumar Patel is a Hematologist practicing medicine in Urbana, Illinois. He has been practicing medicine for over 18 years. Dr. Patel is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Plasmacytoma, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Patel is currently accepting new patients.

Expertise in
42
conditions
Dr. Kuppuswamy Jagarlamudi
Hematology | Oncology
Expertise in
42
conditions
Dr. Kuppuswamy Jagarlamudi
Hematology | Oncology
Referral may be required

SBL Regional Cancer Center

1001 Health Center Dr, 
Mattoon, IL 
 (43.7 miles away)
217-258-2250
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kuppuswamy Jagarlamudi is a Hematologist and an Oncologist practicing medicine in Mattoon, Illinois. Dr. Jagarlamudi is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Appendix Cancer, Neuroendocrine Tumor, Paget Disease of the Breast, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Jagarlamudi is currently accepting new patients.

Frequently Asked Questions about Dr. Pratima Chalasani

How do I make an appointment with Dr. Pratima Chalasani?

You can book an appointment with Dr. Pratima Chalasani by calling their office at 217-383-6636. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pratima Chalasani a top-rated expert for Monoclonal Gammopathy of Undetermined Significance (MGUS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pratima Chalasani is classified as an Advanced expert for Monoclonal Gammopathy of Undetermined Significance (MGUS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pratima Chalasani specialize in?

While Dr. Pratima Chalasani is a Hematology, they have specific expertise in Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Pratima Chalasani participate in research or clinical trials?

Yes. Dr. Pratima Chalasani has published 1 articles and abstracts on conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS). You can view a list of Dr. Pratima Chalasani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Pratima Chalasani accept my insurance?

Dr. Pratima Chalasani accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 217-383-6636 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chalasani's expertise for a condition
ConditionClose
      View All 30 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile